Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: Results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007

Clinical Therapeutics

Volumn 30, Issue 11, 2008, Pages 2040-2050

  Dowzicky, Michael J ^a   Park, Choong H ^b  

^a PFIZER INC   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Acinetobacter; antimicrobial resistance; Enterobacteriaceae; Enterococcus faecium; Staphylococcus aureus; tigecycline

Indexed keywords

TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; UNITED STATES;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; POPULATION SURVEILLANCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; TIME FACTORS; UNITED STATES; WORLD HEALTH;

EID: 57649199209     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.11.006     Document Type: Article

References (27)

1. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 42 Suppl 2 (2006) S82-S89
2. Pillar C.M., Draghi D.C., Sheehan D.J., and Sahm D.F. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: Findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. Diagn Microbiol Infect Dis 60 (2008) 221-224
3. Klein E., Smith D.L., and Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13 (2007) 1840-1846
4. Vila J., Martí S., and Sénchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 59 (2007) 1210-1215
5. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 6th ed. (2003), Clinical and Laboratory Standards Institute, Wayne, Pa Approved Standard
6. Reinert R.R., Low D.E., Rossi F., et al. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60 (2007) 1018-1029
7. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement, M100-S16 (January 2006), Clinical and Laboratory Standards Institute, Wayne, Pa
8. Tygacil [product insert]. Philadelphia, Pa: Wyeth Pharmaceuticals Inc; 2005.
9. http://www.wyeth.com/hcp/tygacil Accessed April 22, 2008
10. Isenberg H.D. Essential Procedures for Clinical Microbiology (1998), ASM Press, Washington, DC
11. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement, M100-S18 (January 2008), Clinical and Laboratory Standards Institute, Wayne, Pa
12. Waites K.B., Duffy L.B., and Dowzicky M.J. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 50 (2006) 3479-3484
13. Lockhart S.R., Abramson M.A., Beekmann S.E., et al. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 45 (2007) 3352-3359
14. Landman D., Bratu S., Kochar S., et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 60 (2007) 78-82
15. Sader H, Fritsche T, Stilwell M, Jones R. Escalating resistance among non-fermentative gram-negative bacilli: Report from the North American SENTRY Antimicrobial Surveillance Program (1997-2006). Presented at: 18th European Society of Clinical Microbiology and Infectious Diseases (ESCMID); April 19-22, 2008; Barcelona, Spain.
16. Wareham D.W., Bean D.C., Khanna P., et al. Bloodstream infection due to Acinetobacter spp: Epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 27 (2008) 607-612
17. Jones R.N., Sader H.S., Fritsche T.R., and Rhomberg P.R. Carbapenem susceptibility discords among Acinetobacter isolates. Clin Infect Dis 42 (2006) 158
18. Zavascki A.P., Goldani L.Z., Li J., and Nation R.L. Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J Antimicrob Chemother 60 (2007) 1206-1215
19. Karlowsky J.A., Jones M.E., Thornsberry C., et al. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 47 (2003) 1672-1680
20. Rupp M.E., and Fey P.D. Extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae: Considerations for diagnosis, prevention and drug treatment. Drugs 63 (2003) 353-365
21. Bratu S., Landman D., Haag R., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: A new threat to our antibiotic armamentarium. Arch Intern Med 165 (2005) 1430-1435
22. Rhomberg P.R., Deshpande L.M., Kirby J.T., and Jones R.N. Activity of meropenem as serine carbapenemases evolve in US medical centers: Monitoring report from the MYSTIC program (2006). Diagn Microbiol Infect Dis 59 (2007) 425-432
23. Karlowsky J.A., Draghi D.C., Jones M.E., et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 47 (2003) 1681-1688
24. Tillotson G.S., Draghi D.C., Sahm D.F., et al. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: Laboratory-based surveillance study. J Antimicrob Chemother 62 (2008) 109-115
25. Sader H.S., Jones R.N., Stilwell M.G., et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: A collection from 6 continents. Diagn Microbiol Infect Dis. 52 (2005) 181-186
26. Fritsche T.R., Sader H.S., Stilwell M.G., et al. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn Microbiol Infect Dis 52 (2005) 195-201
27. Treitman A.N., Yarnold P.R., Warren J., and Noskin G.A. Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). J Clin Microbiol 43 (2005) 462-463